Connect with us

Share Market

Uber Share Price vs. Uber Service: The Truth About Big Companies, Popular Products, and Dying Stocks

Published

on


There seems to be so much confusion around the Uber IPO, Uber share prices, and Uber service…

The company’s popular around the globe, right? So why isn’t the stock soaring?

Let’s talk about 2019…

This year, a lot of well-known, popular companies had IPOs — Uber, Slack, and Peloton. These companies produce some of the public’s favorite products … but their stocks are complete garbage.

And all of them have underperformed. And traders still ask, “Is now the time to buy?” Let’s look at these ‘hot’ IPOs and Uber share prices to better understand why these stocks aren’t great for small accounts.

Don’t Fall in Love With a Product

Companies continuously produce new and improved products for the public to love. Once the public bites, media outlets jump on and overhype the companies. The results are huge overvaluations, and it just sets up stocks and traders for disappointment.

Just because a company makes a great product doesn’t mean the company itself is good. There can be a ton of things wrong with a company … But people will overlook huge red flags if they love a specific product. So they look for the right time to jump in.

And as these overvalued companies start to fade, that question keeps popping up: “Is now the time to buy?”

Dip buying on large companies isn’t the same as my dip-buy pattern. It’s challenging to know where the bottom actually is with larger companies. The price could continue to fall for months, like Uber share prices. Let’s check out some recent examples.

Slack Technologies, Inc. (NYSE: WORK)

uber share price vs. uber service: the truth about big companies, popular products, and dying stocks
WORK Chart: 1-year, daily candle — chart courtesy of StocksToTrade.com

Since its June IPO, WORK has basically gone straight down. Although it didn’t dump following its IPO, the stock has consistently declined for months. Specifically, it’s dropped roughly 10% every month since the IPO or nearly 50% from its highs.

I can’t tell you how many traders, investors, advisors, and articles I’ve seen calling every one of the dips the bottom. Like when it dropped from $42 to the $30s, according to the financial media, this was a good dip to buy.

And again, when it dipped from $35 to $31, people said it was absolute panic. They thought that was the bottom … only it continued to drop further.

People thought it was an excellent time to buy when WORK dumped to new lows thinking, “Okay … this is down from $42 to $26. This 100% has to be the bottom.

That mindset is a slippery slope. I always follow rule #1 and cut losses quickly. I don’t hold and hope. Anyone who believed in WORK as a company and bought at the “bottom” lost a lot of money.

Don’t get me wrong, I like Slack’s product. I know a lot of people who like Slack and use it every day. But you can’t judge a stock based on a product alone. You have to understand the company’s fundamentals. And even then, these big companies may not be the best investment. That’s just a small piece of the puzzle.

Uber Technologies, Inc. (NYSE: UBER)

Look at Uber share prices and you’ll see another bad IPO. So why is the stock so bad when so many people around the world use its service?

The stock’s down nearly 50% because they have a lot of issues with their cost structure, growth, management, and company culture. I mean, they have endless problems. Uber’s share prices and stock chart speak volumes.

uber share price vs. uber service: the truth about big companies, popular products, and dying stocks
UBER Chart: 1-year, daily candle — chart courtesy of StocksToTrade.com

But if you listen to mainstream media, Uber stock was the greatest buy of 2019. So many pundits and experts hyped UBER as a great buy. People and the media fell in love with the product…

… but they failed to look at all of Uber’s underlying issues. That’s a huge mistake.

Again, I love Uber’s product and will continue to use it. I don’t want to see Uber fail — I’m merely being realistic. Big companies with popular products usually aren’t the best investments.

None of my millionaire and six-figure students made their profits investing in these large, overvalued companies. They used predictable and repeatable patterns like the ones I teach in my Trading Challenge.

Peloton Interactive, Inc. (NASDAQ: PTON)

Uber and Slack aren’t the only failures. This pattern happens every year with several companies. Peloton, the indoor cycling company, was supposed to be a hot IPO this fall.

But what really happened?

uber share price vs. uber service: the truth about big companies, popular products, and dying stocks
PTON Chart: 1-year, daily candle — chart courtesy of StocksToTrade.com

Not much. It dipped a little off its IPO price and has been chopping around. It’s nearly impossible to grow a small account with this price action. That’s why I only trade penny stocks.

Again, don’t confuse the stock and the product. Here’s one last example for you…

Celsius Holdings, Inc. (NASDAQ: CELH)

I drink Celsius. I think it’s a great pre-workout drink, kinda like a healthy energy drink. A lot of health-conscience fitness professionals recommend their product.

Theoretically, this should do very well. But, over the past two years, CELH has done nothing.

uber share price vs. uber service: the truth about big companies, popular products, and dying stocks
CELH Chart: 2-year, daily candle — chart courtesy of StocksToTrade.com

Even some of the world’s wealthiest people invested in Celsius, but it’s failed to perform. Li Ka-Shing, the world’s 30th richest person, is an investor who planned to bring the drink to Asia. Celsius should’ve been a big hit there. For whatever reason, it’s not taking off.

I can’t say this enough. Trading isn’t about the product or the quality of the company.

And if you’re trying to grow a small account, getting 10% growth a year (which is considered good on Wall Street) won’t help you much. What can work for your small account? Day trading penny stocks.

Need a place to start? Check out my free penny stock course here.

Stay Out of Dying Stocks

uber share price vs. uber service: the truth about big companies, popular products, and dying stocks
© 2019 Millionaire Media, LLC

You can’t hold and hope. Well … you can, but it’s not a strategy, and it doesn’t work.

I hate seeing traders fail. Trust me, I personally love a lot of the products these companies have created. I even use a lot of them, but that’s not enough for me to trade these tickers.

If trading has taught me anything, it’s that the stock market will never value a company based on people’s reaction to the product or service. I know people still think that’s possible because that’s maybe what happened in the market a few decades ago.

Unfortunately, after a 10+ year bull market, you can’t rely solely on a popular product.

tim sykes watchlist banner

For example, if you want a company’s stock to go up, the company will have to come out with new products. Especially with big, multi-billion-dollar companies like Uber or Slack. Also, the product can’t be a fad, and the company also needs to be structurally sound. Even if a company has everything going for them, there’s no guarantee the company’s stock will spike.

I see this trend again and again. It’s challenging for people trying to get into the stock market. Many are busy and think…

“Hey … I just want to invest. I want to invest in what I know!”

That’s a popular adage in the market, “invest in what you know.” But people take it too literally. And sadly, it’s not that simple. People like to oversimplify things.

Popular Products, Good Companies

I’m not saying this strategy never works — sometimes it does. Starbucks is near its highs. Sometimes, people love the product and the stock, like Chipotle.

Chipotle had some food safety issues, and the stock got crushed 50%. But the company is solid, and people continue to love its product. Now it’s right back at all-time highs.

uber share price vs. uber service: the truth about big companies, popular products, and dying stocks
CMG Chart: 2-year, daily candle — chart courtesy of StocksToTrade.com

But there’s no discernible pattern with these big companies.

Nike (NYSE: NKE) is near its highs, but you don’t know what will happen next. A lot of people love and use Twitter (NYSE: TWTR) … but it’s been very choppy over the last two years. A huge portion of the business world uses Microsoft (NASDAQ: MSFT), which just hit all-time highs as of this writing. There are just too many factors to consider.

The Reality of Wall Street

uber share price vs. uber service: the truth about big companies, popular products, and dying stocks
© 2019 Millionaire Media, LLC

You can’t guess a company’s value solely based on personal experience. These simple assumptions don’t make for smart, self-sufficient trading.

Let’s say you pick your 10 favorite products and buy the stocks. Maybe you’d get lucky and buy the next Microsoft. But more times than not, you won’t grow your account that way.

If you look at Uber share prices now — and you bought in on day one — you probably already know this lesson firsthand.

Learn from that experience. Learn from my experience. Focus on how you can be a smarter trader and adapt to the market. That’s exactly what I teach my students in my Trading Challenge. Apply today.

Learn patterns like the ones I explain in my How To Make Millions DVD. These penny stock patterns are far less talked about and less counterintuitive.

What do you think about ‘hot’ IPOs? I love to hear from you!

The post Uber Share Price vs. Uber Service: The Truth About Big Companies, Popular Products, and Dying Stocks appeared first on Timothy Sykes.



Source link

قالب وردپرس

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Share Market

Trading Mindset: How to Get It Right (and the Biggest Mistakes to Avoid)

Published

on


Finding success in the stock market is so much more than learning patterns. You need to have the right trading mindset.

Don’t get me wrong, patterns are essential and important. In fact, I think anyone can learn my penny stock patterns that present themselves every day in the stock market … As long as they put in the time…

You gotta practice. If you want a risk-free way to learn, you can do that on the StocksToTrade platform and paper trade. Or if you’re ready to start with real money, you can trade small.

And as you start your trading career, it’s imperative that you work to develop the right trading mindset.

Your mindset is the foundation for every trade and your entire trading career. It’s something that you have to hone and refine all the time. I know that personally from trading for 20+ years. If I don’t check my mindset, I run the risk of overtrading.

That’s exactly why I’m dedicating this post to the trading mindset. Because the wrong approach to the markets can lead to loss of confidence, chasing trades, and even blown-up accounts.

Let’s get to it!

What Is the Trading Mindset?

© 2020 Millionaire Media, LLC

The trading mindset is really a set of rules for how you’ll conduct yourself as a trader and in the markets. And you can actually apply it to a lot of other aspects of life — not just trading.

During my two decades of experience in trading penny stocks, I’ve learned key facets of the trading mindset. That’s what I base my trading rules on. My top students know just how important it is to follow these rules to become self-sufficient in the markets.

So let’s break down the rules that go into the right trading mindset … and the biggest mistakes you should avoid as a trader.

Let’s start with my #1 rule…

Cut Losses Quickly

When it comes to trading penny stocks, this is the most important thing both new and veteran traders focus on.

My newest six-figure students like Matthew Monaco, Jack Kellogg, and Kyle Williams swear by this rule.* It’s a big part of what’s helped them to grow their accounts. It’s not just how you win — it’s also how you manage your losses.

You have to cut losses quickly because penny stocks are volatile. They can make rapid gains and lose them just as fast. Too many newbie traders think these crap penny stocks will be the next Amazon or Netflix. But that’s just not the case.

A lot of these companies dilute their stock to raise money for execs and insiders. That’s what we call toxic financing. It’s a big reason you don’t hold a penny stock position and hope for the best.

Learn the patterns and how to trade them. When a trade doesn’t go as you expect, get out.

When I trade, I keep my losses small and let my winners run — even if it’s only 20%–30%. Which brings me to my next key rule…

Learn to Take Singles

Too many traders want every trade to be a 100%+ home run. We’ve seen some astounding moves in the wild pandemic market … but that’s not typical. And even Wall Street aims for about 8%–10% per year.

This rule goes back to cutting losses quickly. Once, I lost over $500K in one trade because I didn’t cut losses. You can read about that in my free book,An American Hedge Fund.”

After learning that lesson the hard way, I shifted my strategy to trade more conservatively. And if you’re managing your risk, those singles add up over time. That’s how you build a small account, and exactly what I teach in my Trading Challenge.

Here’s what you don’t do…

Hold and Hope

Holding and hoping is one of the biggest mistakes I see new traders make. It’s nothing new. A new hot sector pops up, and suddenly ‘gurus’ lure uneducated newbies into stocks that ultimately fail.

Most penny stocks won’t become large-cap stocks. Don’t look at these trades as investments…

That’s the wrong trading mindset. Maybe a few of these sketchy will become real companies one day. But I don’t like those odds, and I’m not that patient. I’d rather take my quick singles trades and let them add up.

I teach my Challenge students to do the same. Let’s look at an example of how I trade with the right tools and the trading mindset…

Artificial Intelligence Technology Solutions Inc. (OTCPK: AITX)

I took this trade because it’s a former runner with coronavirus-related news. I got in the trade early at $0.023 per share thanks to the StocksToTrade Breaking News add-on. Check out the chart:

AITX stock chart
AITX chart: 5-day, 1-minute candles — courtesy of StocksToTrade.com

I ended up selling at $0.032 per share for a $1,600 gain, which you can check out on Profit.ly.*

This was a 39% gain, which is bigger than my average. But I waited for the right setup, then I took my single and got out.

You don’t need to aim for 100% or more for winning trades. Again, trades like this add up over time. I’m up over $5.5 million in trading profits over my past 20 years of trading.* And I didn’t do it through holding and hoping.*

(*My results, along with the results of my top students are far from typical. Individual results will vary. Most traders lose money. My top students and I have the benefit of many years of hard work and dedication under our belts. Trading is inherently risky. Do your due diligence and never risk more than you can afford to lose.)

Notice I mentioned former runners? This is exactly why you need to…

Study the Past

History repeats. I often say I’m just a glorified history teacher. I’ve been trading the same patterns for over 20+ years in the market. It’s not exactly the same — I have to adapt to what the market is giving me right now.

But too many traders think studying the past is a waste of time. Then they ask me how I know about former runners or how to spot my favorite patterns again and again.

You have to prepare. If you study what stocks moved in past pandemics like Ebola or SARS, you’d know to watch a lot of stocks that spiked in the current pandemic. I broke some of those down in this post.

There’s not just one thing you can focus on in the markets. You have to learn it all. That’s how you…

Work to Become a Self-Sufficient Trader

All the watchlists and alerts I send out to subscribers aren’t to get them to blindly follow my picks. In reality, the stocks in the penny stock niche can move so fast that by the time I send out the alert, it’s too late.

So why do I send them? To teach the process. I want you to understand why I picked those stocks. It’s another opportunity for you to study. What was the catalyst, the volume? How high did the spike run? Was it a short squeeze — and how can you tell?

My top Challenge students are self-sufficient traders. They learned my rules and strategies and then made them their own. Some even out trade me. Like Tim Grittani, arguably the best trader ever.

Start your learning process — sign up for my no-cost weekly watchlist here.

There’s something you have to always remember…

Discipline Is Key

You can learn all the right rules and strategies, but if you don’t stay focused and disciplined with the right trading mindset … you’re putting your trading career in jeopardy.

This another lesson I’ve learned the hard way. It’s why I trade like I’m a retired trader. A setup has to be so good, I’d feel awful for missing it.

That mindset helps me to not overtrade. Not gonna lie, it’s hard in this wild market. There are SO many hot plays. The volatility is insane. And I’m thrilled that all my wins will help someone in need since I donate all my profits to charity and causes like my Yemen fundraiser.

watchlist banner

Get smart tips for navigating this volatile market — and any future volatility. I put together this no-cost two-hour video lesson to help you get through it. Get access to “The Volatility Survival Guide” here.

But the market won’t be like this forever. It’s bound to slow down. So overtrading now can mess with your mindset. You risk learning the wrong lessons and losing more when the market slows down.

I’d rather see students make a few good trades per week than take a bunch of subpar trades. That’s especially true if you trade with a small account. If you use a cash account and aren’t limited by the PDT rule, it can be easy to take more speculative plays rather than waiting for a great pattern.

Don’t do it! And in this niche, always…

Expect the Worse

If you expect the worse out of these companies, you’ll never be disappointed.

Don’t believe the hype you see on Twitter. This is where the new promoters are. They love to tout these stocks. You can’t fall for it. Don’t fall in love with stocks — trade them and move on.

When I started in the markets, I was a young guy looking to make money in the markets. I had to learn to trade the hard way — through trial and error. Along the way, I had some big wins … and losses. I didn’t have a trading mentor.

There was no one willing to share what they knew about this industry.

That’s why I started teaching. I want to help dedicated students become self-sufficient traders. You can’t do that unless you really understand this industry.

People love to hate on penny stocks, but they don’t understand how to play the game. They don’t understand how to slowly build a small account. So here’s my last tip on how to get into the right trading mindset…

Build Your Knowledge Account

The best part? You can choose your level of commitment based on what works for you.

Start with my FREE online guide to penny stocks.

You can follow me on Twitter and on my YouTube channel. I release new trading articles and videos all the time.

You can get my student Jamil’s book “The Complete Penny Stock Course” to get a thorough overview of all my core lessons.

supernova placement

You can join Pennystocking Silver for access to over 6,000 video lessons and more.

And when you’re ready for the ultimate trading commitment, you can apply for my Trading Challenge. That’s where all my top students started. It includes access to the best chat room and trading community, live webinars, DVDs, and so much more.

It’s not easy. It’s taken all my top students years of hard work and studying to hit their market stride. But if you’re in the Challenge, you can trade right alongside them.

Think you have the discipline to make it in the Trading Challenge? Apply today and find out.

The Trading Mindset Conclusion

At the end of the day, there’s no single right way to trade.

What matters is your right trading mindset. Without discipline, it’s near impossible to make it in trading or to grow and protect your account. You gotta follow rules like cutting losses quickly and taking those singles.

You have to study every day.

If you’re serious about learning how to trade penny stocks, apply to my Trading Challenge.

What’s your biggest trading mindset issue? Let me know in the comments below!

The post Trading Mindset: How to Get It Right (and the Biggest Mistakes to Avoid) appeared first on Timothy Sykes.



Source link

قالب وردپرس

Continue Reading

Share Market

DECN – Some DD for you on this Saturday

Published

on



DECN is a company that was founded in the early 2000s. Before COVID-19 shocked the world, their product was(and still is) an at-home blood glucose testing strip; these items can be found on Amazon and a plethora of other medical sites.

On March 3rd, 2020, they announced an introduction to their screening method for COVID-19.

"Our product is timely, simple to use, cost-effective, and will be commercially ready in the summer of 2020."

"I want to say straight on that we have developed a Coronavirus screening method, not a cure or a vaccine for this virus. That being said, our screening method should allow for 80% of the suspected carriers of Coronavirus to exit the quarantine systems in the places where Coronavirus is rampant."

https://www.accesswire.com/578719/DECN-Jumps-into-Screening-and-Testing-Channel-For-Coronavirus-COVID19-Using-Its-Innovative-Impedance-Technology-First-Implemented-In-Its-GenUltimate-TBG

Before this announcement, the stock was trading sub $0.02. On March 3rd, the stock reached a peak of $0.045.

—————————————————————————————————————————————————–

The next day, they had more PR come out that stated the following:

"….. GenViro for the Coronavirus (covid19) began as an outgrowth of our GenUltimate TBG product line. What makes the testing for the Coronavirus possible, and the GenUltimate TBG special is the company's Impedance measurement technology."

https://www.accesswire.com/578869/DECN-Fills-in-the-Gaps-Adds-to-Knowledge-Base-for-its-GenViroTM-Coronavirus-Covid19-Multi-Dimensional-Diagnostic-Methodology-Announced-March-2

DECN's stock price stayed within the $0.03-$0.04 range with this PR

—————————————————————————————————————————————————–

On March 11th, just a week after their first announcement, they put out a PR that started a lot of buzz and hype.

"Today… we present the Coronavirus test kit and the Phase 1 unit forecast… We anticipate the sale of 420,000,000 kits in the first full year of commercial sale. The company has retained FDA counsel who is in the process of securing expected emergency waiver for diagnostics and diagnostic devices."

"Keith Berman, CEO of DECN commented, "Because we perfected the Impedance technology in 2019 for our GenUltimate TBG glucose test strip and meter, we have shaved months off of the development time for the GenViro! device."

https://www.accesswire.com/579985/DECN-Provides-First-Looks-At-Its-GenViroTM-Corona-Virus-Screening-Kit-First-Year-Product-Forecast-of-420-Million-Kits-with-Sales-Beginning-Late-3Q-2020

This caused the stock price to jump from sub $0.025 to over $0.07; within a week it went up 350% and started gaining a lot more eyes due to how big this virus was starting to get around the world.

—————————————————————————————————————————————————–

Over the coming weeks, they would put out more and more PR highlighting the product previously spoken about, and this would gain the eyes of a lot of investors because of how rapidly the virus was spreading.

Some key quotes from their PR:

"We are awaiting (the) release of blood samples from previously infected people in Daegu, Korea, so that we can complete testing and make a final report to the U.S. FDA so that we may secure our Emergency Waiver."

https://www.accesswire.com/580769/DECN-Updates-on-Its-Corona-Virus-Testing-Product-GenviroTM-With-200000-Kits-to-Be-Provided-in-USA-EU-Prior-to-the-Summer-12-Month-Forecast-Updated-to-480mm

"We are happy to inform all interested parties that we have raised our 12-month forecast to 525 million kits."

"… receiving a plan from our technical and R&D director, we decided to take the next step with GenViro™and further refine its use for hospitals. While we have not yet forecast sales to hospitals, and while most of the lesser but competitive products are directed toward hospital uses, we nonetheless believe that hospitals will be a large future source of revenues."

https://www.accesswire.com/581057/DECNS-GenViroTM-Corona-Virus-Swift-Kit-Now-to-Be-Additionally-Offered-to-Commercial-Labs-and-Religious-Groups-as-12-Month-Forecast-is-Raised-to-525MM

"Mr. Berman concluded, "I have been in and around the in-vitro diagnostics business for over 40 years, and never before in all of that time, have I witnessed a policy like this. This latest guidance from the FDA shaves months from our product development process, and we all shall reap these benefits. Tomorrow we will discuss our new plans going forward now that we will shortly be a two product coronavirus diagnostics company."

https://www.accesswire.com/581231/DECNs-GenViroTM-COVID-19-Rapid-Kit-to-Reap-Huge-Boost-from-316-FDA-Guidance-Allowing-for-Near-Immediate-Distribution-of-Kits-Prior-to-Emergency-Waiver-Grant

"DECN announces that the company's Board of Directors has approved the offering of $13 million in non-dilutive debt financing, the first $2 million in Notes, followed by a $1 million credit facility to purchase manufacturing equipment for their Korean manufacturing facility, and the remaining $10 million in a revolving line of credit to finance inventory."

https://www.accesswire.com/581701/DECN-to-Finance-2Q-2020-Roll-Out-of-its-GenViro-Covid-19-Rapid-Kits-Using-Non-Dilutive-Debt-Financing-Totaling-13-Million-Acquired-in-Near-0-Rate-Environment

At this point, the stock that originally was trading below $0.02 is now trading near $0.26.—————————————————————————————————————————————————–

***** "GenViro! provides results in 15 seconds, based on a small finger-prick blood sample. The method is safe, effective, and its biggest benefit to the healthcare system is that the device can be used to screen out the 97% or 98% of those tested that are negative for COVID-19. Our method is quicker, provides the desired result, is much cheaper, and effective." ***** – March 23rd

https://www.accesswire.com/582023/DECN-Finalizes-FDA-Pre-EUA-Version-of-Its-Genviro-Screening-Covid-19-Swift-Kit-Providing-Results-in-15-Seconds-Using-Only-10-20-Microliters-Whole-Blood

Over the coming weeks, they release more and more PR, all leading up to April 23rd, where they announce a 2nd EUA application, followed by a response from the SEC.

—————————————————————————————————————————————————–

Before April 23rd, the stock was now trading around the $0.40 mark, an astounding jump in share price from what it was trading at pre-test kit.

"The company's goal for GenViro! is not just to receive EUA approval from the FDA, but when this approval is received, to become the go-to testing solution, in demand by Professional organizations as well as Fortune 500 companies, even sports teams"

"New markets for our GenViro! have also been recently identified, the latest — large businesses, Fortune 500 companies, seeking to reopen for business in the next month or two…. Some of these businesses have already contacted the company and even tried to place large purchase orders for GenViro! Swift kits, using the first in line principal, so that they may test and retest returning employees. No other test kit can accomplish this."

https://www.accesswire.com/586571/DECN-To-Submit-Second-EUA-Application-For-Covid-19-15-Home-Testing-GenViro-Swift-Kit-Reports-Huge-Response-From-Fortune-500-Companies

Then, the SEC announces the following:

"The Commission temporarily suspended trading in the securities of DECN because of questions regarding the accuracy and adequacy of information in the marketplace since at least March 3, 2020."

https://www.sec.gov/litigation/suspensions/2020/34-88735.pdf

The stock has a sudden fall to the $0.20 mark and is suspended from trading for 10 days

—————————————————————————————————————————————————–

DECN puts out a response 4 days later

"Prior to the trading suspension Keith Berman, DECN's CEO, had voluntarily submitted to over three hours of interviews conducted by SEC staff members over multiple days. At the conclusion of the second interview, a third interview was requested by the staff. Instead, the SEC suspended trading without warning or further discussion.""Despite the interim trading suspension… intends to press its negotiations with the FDA for expedited approval of the company's GenViro! Swift Kit for the testing of the Covid-19 virus."

https://www.accesswire.com/587124/DECN-Strongly-Questions-SECs-Unilateral-Imposition-Of-10-Day-Trading-Suspension–Company-Is-Undaunted-And-Still-Seeks-Expedited-FDA-EUA-Approval-For-Genviro-Swift-15-Virus-Test-Kit

Even with the SEC halting the trading of their stock, they continue to press with the kit that is being put into question.

—————————————————————————————————————————————————–

The day the stock became un-halted, it fluctuated from $0.015 to $0.21. May 15th, DECN responded with an amended petition for their trading suspension:

https://www.sec.gov/litigation/apdocuments/3-19788-event-2020-05-15-amended-petition-for-termination-of-suspension-of-trading-in-the-securities-of-decision-diagnostics.pdf

—————————————————————————————————————————————————–

May 20th, SEC publishes their information at the time of the suspension:

https://www.sec.gov/litigation/apdocuments/3-19788-event-2020-05-20-information-before-the-commission-at-the-time-of-the-trading-suspension-and-declaration-of-carlisle-e-perkins.pdf

—————————————————————————————————————————————————–

May 21st, DECN publishes their testing results for interested parties.

"Both of our Covid-19 test kits are now in the FDA EUA review process. The company has received Pre-EUA Acknowledgement letters from the U.S. FDA for (the) device (serial number) PEUA200232, GenViro Covid-19 Screening Kit for professional use in commercial and group settings and device (serial number) PEUA200947, GenViro Covid-19 Screening Kit for at-home use."

https://finance.yahoo.com/news/decn-publish-specific-testing-completed-141500448.html

—————————————————————————————————————————————————–

June 17th, DECN responds to the SEC information:

https://www.sec.gov/litigation/apdocuments/3-19788-event-2020-06-17-petitioner-brief-in-support.pdf

They also apply for a provisional patent for their test-kit:

https://finance.yahoo.com/news/decn-files-provisional-patent-genviro-142000019.html

—————————————————————————————————————————————————–

***************************************************************************************

July 1st, the SEC releases the final documentation for the petition on the suspension of trading:

"… the Commission’s opinion that the public interest and the protection of investors required suspension of trading in DECN’s securities was the right decision and remains the right decision. Accordingly, the Petition should be denied."

https://www.sec.gov/litigation/apdocuments/3-19788-event-2020-07-01-divisions-brief-in-opposition.pdf

Read this, at the very least, if you are going to buy this stock.

***************************************************************************************

—————————————————————————————————————————————————–

July 2nd, CEO Keith Berman releases an open letter:

"Public health experts seem to agree on two things, the need for a vaccine and the importance of increased, immediate, and affordable testing to determine exactly who is ill and contagious. As New York Governor Andrew Cuomo stated, "The more testing, the more open the economy." The President's Advisory Task Force agrees that the economy won't open completely and remain such without wide-scale testing."

"But, testing is only valuable when it is accurate. In the case of a pandemic, it must also be affordable and produce reliable results in minutes, even seconds. On that front, there has to date been a failure to deliver. "

"Companies large and small have jumped in headfirst to the testing race under the FDA's guidance and with big dollars on the line. Unsurprisingly, that favors the large players to the detriment of smaller, often more nimble and innovative players. In the end, it's the public health, really all of us, who suffer. Another article points out the FDA's oversight has been inconsistent at best, stating, "The FDA must stick to its normal process for review but expedite it by giving it top priority with its clinical reviewers and bring in more reviewers if necessary."

"More so, our public health administrators favor familiar technologies whose applications often don't respond to the exact urgent needs of the moment. Worse yet, they seek familiar faces, often the big pharma-med-tech players, who like an oil tanker in the open ocean, take forever to change course in the direction required. Unfortunately for us all, this frequently unfolds at the immediate expense of creative, alternative thinking, new, unknown, smaller players who may actually have the answers, but rarely get the chance and support to appropriately test their solutions."

https://www.accesswire.com/596043/DECN-CEO-Offers-Open-Letter-on-COVID-19-Testing-Highlighting-Needed-Support-for-Innovation-in-Testing

There are a ton of quotes from this letter, but I wanted to point out a few.

—————————————————————————————————————————————————–

July 8th, DECN announces distribution:

"The company plans to manufacture two GenViro! International Covid-19 Swift Kit packages for sale in Central and Southern Asia and reports that its new distributor will be opening hubs in Singapore, India, and Australia… The company still estimates that sales for its International GenViro! Swift Kits will commence in late Summer 2020."

https://www.accesswire.com/596668/DECN-Announces-Distribution-Agreement-Covering-GenViro-Covid-19105-Swift-Kits-and-Its-GenUltimate-and-TGB-Products-in-India-Malaysia-Sri-Lanka-Singapore-Indonesia-Thailand-Vietnam-Nepal-Bangladesh-and-Australia

—————————————————————————————————————————————————–

July 10th, DECN announces a saliva COVID-19 test-kit for professional and home use, as well as re-iterating their blood-prick test-kit is showing results within 11 seconds:

"Test reporting for the GenViro! finger stick kits are currently producing results at :10.5 seconds, and initial testing completed on the saliva version of the kit should yield even faster results since the saliva testing will not require any sample correction."

"Preliminary testing… was run using saliva from human donors and indicated that the saliva exhibits a comparable, and in fact favorable, impedance curve profile when compared to whole blood."

https://www.accesswire.com/596976/DECN-to-add-GenViro-Saliva-Covid-19-Swift-Kit-105-for-Professional-and-Home-Use-Testing-Providing-an-Alternative-Modality-to-its-Finger-Stick-Methodology

—————————————————————————————————————————————————–

What does this all mean?

DECN says they have a product that will literally have an impact on the world; we need to test everyone and we need to do it in a way that is easy, yet effective. The fact they claim they can make upwards of 500 million test kits within a year of production shows the scale that they are able to bring their product.

The risk:

– This is an OTC, so it is inherently more risky than other stocks

– This stock will not go up any more than it is currently at now without the EUA from the FDA

– It is still on the Grey Market(normal stocks are on pinks) and you may not even be able to buy it currently, DECN has to submit form 211 in order to get themselves off the grey market; to my knowledge, they have not done this yet

– On a scale of 1-10, 1 being a low risk and 10 being high, I would have to give it a solid 7.5-8.5; again, this stock will not move without the FDA approving their device

The reward:

– You get in on the low of a stock that has the potential to raise upwards over 1-5$; my PT has been laughed at many times, but think about it… 500 million test kits, $6.95 wholesale price per test kit… stocks with this much in earnings are not penny stocks

Why I believe in this company:

If you double, triple, and quadruple down, saying that you have a product that can produce the results you promise, and then you continue to put out PR that you have come to agreements for distribution, preparing for the moment you get the approval, you would need to actually have that product. The US is seeing the 2nd wave, and this virus is not going to leave our lives for the foreseeable future.

My predictions for the stock:

– If FDA approval comes before it moves off the grey market: $0.70-$0.95

– If it moves off the grey before FDA approval: $0.40-$0.55

– Once it has both FDA approval and is moved off the grey market: $1.00-$1.25

TLDR: DECN claimed to have a quick testing process for COVID-19, SEC halted them due to the belief of misinformation. DECN denounces the halt, still pushes forward with trying to get the EUA from the FDA. DECN has since released multiple statements that they have a product and it does produce the results they previously stated. No EUA has been given to DECN yet, no movement off of the grey market yet, VERY RISKY STOCK TO BUY, but also could be more rewarding than others once they get all of the previously stated items.

submitted by /u/Fador33
[comments]



Source link

قالب وردپرس

Continue Reading

Share Market

Wall Street Week Ahead for the trading week beginning July 13th, 2020

Published

on



Good Friday evening to all of you here on r/StockMarket. I hope everyone on this sub made out pretty nicely in the market this past week, and is ready for the new trading week ahead.

Here is everything you need to know to get you ready for the trading week beginning July 13th, 2020.

Market heads into worst earnings season in 12 years amid worries virus is slowing recovery – (Source)


The worst earnings season in years is about to begin, and it’s possible the stock market could shrug off the sharp profit decline, as long as companies see some signs of a recovery ahead.


Earnings are expected to fall by 44%, the worst quarterly performance since the Great Recession when S&P 500 profits fell by 67% in the fourth quarter of 2008, according to Refinitiv I/B/E/S data. It is also expected to be the worst quarter of the pandemic crisis, revealing the extent of the earnings damage as the economy slumped more than 30%.


Major financials JPMorgan, Bank of America, Goldman Sachs and Wells Fargo are among the financial firms reporting. Pepsico starts off the week with its report Monday, and Johnson and Johnson, Abbott Labs and Netflix also report.


The financial sector is expected to see a more than 52% decline in profits, according to Refinitiv.


“U.S. companies are about to give us a look into their worst quarter since the Great Financial Crisis,” said Lindsey Bell, chief investment strategist at Ally Invest. “But since so many companies aren’t giving earnings forecasts, investors won’t make moves based on earnings alone. They’ll also be looking at trends since the quarter ended. Increasing coronavirus cases, management outlooks, and price performance could all have an outsized impact, and that could lead to outsized market moves.”


Stocks turned in a mixed performance in the past week, reacting at times to the rising risks to the economy as coronavirus cases continued to increase in some states. The Dow posted a weekly gain of 0.96% while the S&P 500 and Nasdaq were up 1.76% and 4.01%, respectively.


In the week ahead, there are some important economic reports, including CPI inflation data Tuesday and retail sales Thursday. Last month, retail sales rose a surprise 17.7% but this month economists are watching closely to see if the reversal of some openings and the delays in other is impacting consumer spending.


But it’s the earnings that could be a litmus test for markets.


“I think it really comes down to earnings, not what the numbers are going to be. People don’t care about the numbers. They want to hear what the companies have to say,” said Peter Boockvar, chief investment strategist at Bleakley Adivsory Group. “Tech companies are going to have the most important earnings. Companies like semiconductors, that go into automobiles, computers and cell phones. They’re the ones that have to say our outlook is great, and therefore our stocks deserve to be at all-time highs.”


Tech company earnings are only expected to fall by 8%. The worst sectors are expected to be energy, with a decline of 154%, followed by consumer discretionary, expected to be down by 114%, according to Refinitiv.


This past week saw the following moves in the S&P:

(CLICK HERE FOR THE FULL S&P TREE MAP FOR THE PAST WEEK!)

Major Indices for this past week:

(CLICK HERE FOR THE MAJOR INDICES FOR THE PAST WEEK!)

Major Futures Markets as of Thursday's close:

(CLICK HERE FOR THE MAJOR FUTURES INDICES AS OF THURSDAY!)

Economic Calendar for the Week Ahead:

(CLICK HERE FOR THE FULL ECONOMIC CALENDAR FOR THE WEEK AHEAD!)

Percentage Changes for the Major Indices, WTD, MTD, QTD, YTD as of Friday's close:

(CLICK HERE FOR THE CHART!)

S&P Sectors for the Past Week:

(CLICK HERE FOR THE CHART!)

Major Indices Pullback/Correction Levels as of Friday's close:

(CLICK HERE FOR THE CHART!

Major Indices Rally Levels as of Friday's close:

(CLICK HERE FOR THE CHART!)

Most Anticipated Earnings Releases for this week:

(CLICK HERE FOR THE CHART!)

Here are the upcoming IPO's for this week:

(CLICK HERE FOR THE CHART!)

Thursday's Stock Analyst Upgrades & Downgrades:

(CLICK HERE FOR THE CHART LINK #1!)
(CLICK HERE FOR THE CHART LINK #2!)

Does a Weak First Six Months Mean Trouble?

The wild ride of 2020 continues, with the S&P 500 Index down 20% in the first quarter and up 20% in the second quarter. Much like dropping a 20 dollar bill and picking it up, this doesn’t mean you are 20 dollars wealthier. Down 20% and then up 20% actually comes out to a 4% drop for the first half of the year.

What does a negative first half of the year tell us? Turns out, gains could be hard to come by the second half of this year. “Although 2020 is like nothing we’ve seen before, the fact of the matter is a weak first half of the year could mean weaker than normal returns for the rest of the year,” according to LPL Financial Senior Market Strategist Ryan Detrick.

In fact, the S&P 500 had been higher in the first six months of the year a record nine consecutive years before being lower in 2020. Since 1950, there were 48 times when the first six months were higher and the rest of the year gained 77% of the time and added 5.8% on average those final six months. Compare that with when the first six months of the year were lower 21 times, the final six months were higher only 52% of the time and up only 1.2% on average.

As shown in the LPL Chart of the Day, a move higher is quite likely after strength in the first six months of the year, while very modest gains could be in the cards if those first six months underwhelm.

(CLICK HERE FOR THE CHART!)

Earnings Season Lurks

After a relatively quiet week for economic data and practically no earnings reports to speak of, the Q2 earnings season will kick off next week. Normally, earnings season starts quietly with just a handful of reports outside of the major banks, but next week will be relatively busy with some major players on the calendar. Things start off slowly with Pepsi (PEP) on Monday. Tuesday, we’ll get reports from Citigroup (C), Delta (DAL), Fastenal (FAST), JP Morgan Chase (JPM) and Wells Fargo (WFC), all of whom are scheduled to report in the morning. Wednesday’s major reports include Goldman (GS), Progressive (PGR), and UnitedHealth (UNH) in the morning, while Alcoa (AA) will report in the afternoon. Thursday will be the busiest day of the week with too many stocks to list here, but Netflix (NFLX) will highlight the schedule of afternoon reports. Finally, Friday’s key reports include Blackrock (BLK) and State Street (STT).

As far as analyst sentiment stands heading into the current earnings season, while we wouldn't go so far as to say that it has made a full 180-degree turn from last quarter's negative extremes, it has been close. Over the last four weeks, analysts have raised forecasts for 580 companies in the S&P 1500 and lowered forecasts for 419. That works out to a net of 161 or just under 11% of the index. Besides the S&P 1500, six sectors have positive revisions spreads, while just two are negative. Sectors with the most positive revisions spreads include Consumer Staples, Energy, and Technology, while the two sectors with negative spreads are Financials and Real Estate. Financials just can’t find any love these days.

(CLICK HERE FOR THE CHART!)

The "Miracle" Nasdaq 100

For anyone unfamiliar with the 1969 Miracle Mets, the "Amazins" were 10 games out of first place as late as mid-August and then went on to win 38 out of their last 49 games to finish in first place over the Cubs. From there, the Mets went on to win the first World Series in the history of the franchise in what at the time was one of the biggest turnarounds in the history of baseball. Ironically, in 2007, the Mets were on the other end of another historic turnaround after they blew a seven-game division lead with less than a month left in the season by losing 12 of their last 17 games. But that collapse is a story for another time.

Like the Miracle Mets in 1969, the Nasdaq 100 in 2020 has also staged a historic turnaround. After trading up over 10% earlier in the year, the gains quickly evaporated with the COVID outbreak. Within two months, the Nasdaq 100 went from a YTD gain of over 10% to a decline of over 20% by late March. From there, though, the Nasdaq has gone on an epic run, not only erasing all of its losses but also trading to record highs and a gain of over 20% on the year.

(CLICK HERE FOR THE CHART!)

The frequency of positive days for the Nasdaq 100 provides another illustration of the index's strength this year. So far this year, the index has traded higher on 63% of all trading days. That may not sound like much, but if the year were to end today, it would be the highest percentage of positive days for a given year in the Nasdaq 100's history. On a side note, it's interesting to see in this chart how similar the percentage of positive days has been on a year to year basis over time. There has never been a year where fewer than 46% of all trading days have been positive, and prior to 2020, there has never been a year where more than 62% of all trading days were higher.

(CLICK HERE FOR THE CHART!)

China Charges Higher

We've highlighted the run in Chinese equities quite a lot in the last several days, but it keeps getting more and more extreme. With a gain of over 1% overnight, China's CSI 300 not only turned in its eighth straight day of gains but also its eighth straight day of rallying more than 0.5%. In the history of the CSI 300 dating back to 2002, there has only been one other time where the CSI 300 saw eight or more straight daily gains of 0.5%. That was back in April 2007.

(CLICK HERE FOR THE CHART!)

If you don't remember what was going on with Chinese equities back in April 2007, take a look at the chart below. The last time the CSI 300 had a streak of 8+ days of 0.5% daily gains, the CSI had already doubled in the prior six months. From there, though, it went on to nearly double again in the next six months. Eventually the bubble burst, and it wasn't much more than a year later that the CSI 300 was back below where it was in April 2007.

(CLICK HERE FOR THE CHART!)

Gold Cup

The gold ETF (GLD) has gone through a nine-year drought from new all-time highs, but as it gets closer to its prior highs from September 2011, there are three possible upcoming technical set-ups. The first would be a massive multi-year "cup and handle" pattern. You can see the "cup" that has been forming over the last nine years. For the "handle" to form, GLD would need to go into a sideways consolidation phase from here for a bit. Once that consolidation phase occurs, the pattern would suggest a significant leg higher over potentially years (rather than months).

The second — and more negative — setup would be a bearish "double top." This would happen if GLD gets right up to its highs from September 2011 and fails to break through that resistance

Finally, the third setup would simply be a breakout higher from here. GLD could simply continue moving higher and break right through resistance at its 2011 high.

Regardless of what happens, the "cup" that has been forming for nearly a decade now is something you don't see often. It will be interesting to watch this pattern from a technical perspective over the next few months.

(CLICK HERE FOR THE CHART!)

STOCK MARKET VIDEO: Stock Market Analysis Video for Week Ending July 10th, 2020

(CLICK HERE FOR THE YOUTUBE VIDEO!

STOCK MARKET VIDEO: ShadowTrader Video Weekly 7.12.20

(CLICK HERE FOR THE YOUTUBE VIDEO!)

Here are the most notable companies (tickers) reporting earnings in this upcoming trading week ahead-


  • $JPM
  • $PEP
  • $NFLX
  • $WFC
  • $DAL
  • $DPZ
  • $C
  • $BAC
  • $UNH
  • $JNJ
  • $FAST
  • $GS
  • $ABT
  • $FRC
  • $TSM
  • $PNC
  • $ASML
  • $USB
  • $BK
  • $BLK
  • $MS
  • $ERIC
  • $WIT
  • $ALLY
  • $SON
  • $INFY
  • $AA
  • $SCHW
  • $TFC
  • $ANGO
  • $CFG
  • $BMI
  • $HOMB
  • $ALV
  • $RF
  • $PGR
  • $SNBR
  • $STT
  • $KSU
  • $JBHT
  • $WNS
  • $KRUS
  • $AMRB
  • $MRTN

(CLICK HERE FOR NEXT WEEK'S MOST NOTABLE EARNINGS RELEASES!)
(CLICK HERE FOR NEXT WEEK'S HIGHEST VOLATILITY EARNINGS RELEASES!)
(CLICK HERE FOR MOST NOTABLE EARNINGS RELEASES FOR THE NEXT 2 WEEKS!)

Below are some of the notable companies coming out with earnings releases this upcoming trading week ahead which includes the date/time of release & consensus estimates courtesy of Earnings Whispers:


Monday 7.13.20 Before Market Open:

(CLICK HERE FOR MONDAY'S PRE-MARKET EARNINGS TIME & ESTIMATES!)

Monday 7.13.20 After Market Close:

(CLICK HERE FOR MONDAY'S AFTER-MARKET EARNINGS TIME & ESTIMATES!)

NONE.


Tuesday 7.14.20 Before Market Open:

(CLICK HERE FOR TUESDAY'S PRE-MARKET EARNINGS TIME & ESTIMATES!)

Tuesday 7.14.20 After Market Close:

(CLICK HERE FOR TUESDAY'S AFTER-MARKET EARNINGS TIME & ESTIMATES!)

Wednesday 7.15.20 Before Market Open:

(CLICK HERE FOR WEDNESDAY'S PRE-MARKET EARNINGS TIME & ESTIMATES!)

Wednesday 7.15.20 After Market Close:

(CLICK HERE FOR WEDNESDAY'S AFTER-MARKET EARNINGS TIME & ESTIMATES!)

Thursday 7.16.20 Before Market Open:

(CLICK HERE FOR THURSDAY'S PRE-MARKET EARNINGS TIME & ESTIMATES!)

Thursday 7.16.20 After Market Close:

(CLICK HERE FOR THURSDAY'S AFTER-MARKET EARNINGS TIME & ESTIMATES!)

Friday 7.17.20 Before Market Open:

(CLICK HERE FOR FRIDAY'S PRE-MARKET EARNINGS TIME & ESTIMATES!)

Friday 7.17.20 After Market Close:

([CLICK HERE FOR FRIDAY'S AFTER-MARKET EARNINGS TIME & ESTIMATES!]())

NONE.


JPMorgan Chase & Co. $96.27

JPMorgan Chase & Co. (JPM) is confirmed to report earnings at approximately 6:55 AM ET on Tuesday, July 14, 2020. The consensus earnings estimate is $1.26 per share on revenue of $27.12 billion and the Earnings Whisper ® number is $1.37 per share. Investor sentiment going into the company's earnings release has 33% expecting an earnings beat. Consensus estimates are for earnings to decline year-over-year by 51.35% with revenue decreasing by 24.74%. Short interest has decreased by 11.1% since the company's last earnings release while the stock has drifted lower by 4.7% from its open following the earnings release to be 15.4% below its 200 day moving average of $113.76. Overall earnings estimates have been revised lower since the company's last earnings release. On Wednesday, June 24, 2020 there was some notable buying of 12,021 contracts of the $115.00 call expiring on Friday, July 17, 2020. Option traders are pricing in a 7.2% move on earnings and the stock has averaged a 2.2% move in recent quarters.

(CLICK HERE FOR THE CHART!)


PepsiCo, Inc. $134.46

PepsiCo, Inc. (PEP) is confirmed to report earnings at approximately 6:00 AM ET on Monday, July 13, 2020. The consensus earnings estimate is $1.25 per share on revenue of $15.68 billion and the Earnings Whisper ® number is $1.28 per share. Investor sentiment going into the company's earnings release has 54% expecting an earnings beat. Consensus estimates are for earnings to decline year-over-year by 18.83% with revenue decreasing by 4.68%. Short interest has decreased by 22.7% since the company's last earnings release while the stock has drifted lower by 1.7% from its open following the earnings release to be 0.5% above its 200 day moving average of $133.80. Overall earnings estimates have been revised lower since the company's last earnings release. On Friday, July 10, 2020 there was some notable buying of 2,083 contracts of the $128.00 put expiring on Friday, July 17, 2020. Option traders are pricing in a 3.8% move on earnings and the stock has averaged a 2.0% move in recent quarters.

(CLICK HERE FOR THE CHART!)


Netflix, Inc. $548.73

Netflix, Inc. (NFLX) is confirmed to report earnings at approximately 4:00 PM ET on Thursday, July 16, 2020. The consensus earnings estimate is $1.83 per share on revenue of $6.07 billion and the Earnings Whisper ® number is $1.89 per share. Investor sentiment going into the company's earnings release has 79% expecting an earnings beat The company's guidance was for earnings of approximately $1.81 per share. Consensus estimates are for year-over-year earnings growth of 205.00% with revenue increasing by 23.30%. Short interest has decreased by 27.6% since the company's last earnings release while the stock has drifted higher by 27.7% from its open following the earnings release to be 52.5% above its 200 day moving average of $359.71. Overall earnings estimates have been revised higher since the company's last earnings release. On Friday, July 10, 2020 there was some notable buying of 21,104 contracts of the $550.00 call expiring on Friday, July 17, 2020. Option traders are pricing in a 9.2% move on earnings and the stock has averaged a 4.1% move in recent quarters.

(CLICK HERE FOR THE CHART!)


Wells Fargo & Co. $25.47

Wells Fargo & Co. (WFC) is confirmed to report earnings at approximately 7:55 AM ET on Tuesday, July 14, 2020. The consensus estimate is for a loss of $0.07 per share on revenue of $18.61 billion and the Earnings Whisper ® number is ($0.13) per share. Investor sentiment going into the company's earnings release has 10% expecting an earnings beat. Consensus estimates are for earnings to decline year-over-year by 105.38% with revenue decreasing by 29.71%. Short interest has decreased by 3.9% since the company's last earnings release while the stock has drifted lower by 20.1% from its open following the earnings release to be 38.0% below its 200 day moving average of $41.09. Overall earnings estimates have been revised lower since the company's last earnings release. On Friday, July 10, 2020 there was some notable buying of 7,754 contracts of the $26.00 call expiring on Friday, July 17, 2020. Option traders are pricing in a 9.1% move on earnings and the stock has averaged a 3.0% move in recent quarters.

(CLICK HERE FOR THE CHART!)


Delta Air Lines, Inc. $27.09

Delta Air Lines, Inc. (DAL) is confirmed to report earnings at approximately 7:00 AM ET on Tuesday, July 14, 2020. The consensus estimate is for a loss of $4.06 per share on revenue of $2.17 billion and the Earnings Whisper ® number is ($3.98) per share. Investor sentiment going into the company's earnings release has 3% expecting an earnings beat. Consensus estimates are for earnings to decline year-over-year by 272.77% with revenue decreasing by 82.69%. Short interest has increased by 8.7% since the company's last earnings release while the stock has drifted higher by 13.4% from its open following the earnings release to be 37.3% below its 200 day moving average of $43.23. Overall earnings estimates have been revised lower since the company's last earnings release. On Wednesday, July 1, 2020 there was some notable buying of 16,088 contracts of the $30.00 call and 10,331 contracts of the $26.00 put expiring on Friday, July 17, 2020. Option traders are pricing in a 11.6% move on earnings and the stock has averaged a 1.7% move in recent quarters.

(CLICK HERE FOR THE CHART!)


Domino's Pizza, Inc. $398.31

Domino's Pizza, Inc. (DPZ) is confirmed to report earnings at approximately 7:30 AM ET on Thursday, July 16, 2020. The consensus earnings estimate is $2.24 per share on revenue of $860.80 million and the Earnings Whisper ® number is $2.45 per share. Investor sentiment going into the company's earnings release has 75% expecting an earnings beat. Consensus estimates are for year-over-year earnings growth of 2.28% with revenue increasing by 6.06%. Short interest has increased by 32.3% since the company's last earnings release while the stock has drifted higher by 4.8% from its open following the earnings release to be 25.8% above its 200 day moving average of $316.54. Overall earnings estimates have been revised higher since the company's last earnings release. On Monday, July 6, 2020 there was some notable buying of 915 contracts of the $430.00 call expiring on Friday, August 21, 2020. Option traders are pricing in a 8.4% move on earnings and the stock has averaged a 9.4% move in recent quarters.

(CLICK HERE FOR THE CHART!)


Citigroup, Inc. $52.65

Citigroup, Inc. (C) is confirmed to report earnings at approximately 8:00 AM ET on Tuesday, July 14, 2020. The consensus earnings estimate is $0.55 per share on revenue of $18.11 billion and the Earnings Whisper ® number is $0.55 per share. Investor sentiment going into the company's earnings release has 27% expecting an earnings beat. Consensus estimates are for earnings to decline year-over-year by 69.95% with revenue decreasing by 31.71%. Short interest has increased by 22.2% since the company's last earnings release while the stock has drifted higher by 21.4% from its open following the earnings release to be 15.7% below its 200 day moving average of $62.42. Overall earnings estimates have been revised lower since the company's last earnings release. On Friday, July 10, 2020 there was some notable buying of 21,230 contracts of the $42.50 put and 21,175 contracts of the $52.50 call expiring on Friday, September 18, 2020. Option traders are pricing in a 7.7% move on earnings and the stock has averaged a 2.1% move in recent quarters.

(CLICK HERE FOR THE CHART!)


Bank of America Corp. $24.02

Bank of America Corp. (BAC) is confirmed to report earnings at approximately 6:45 AM ET on Thursday, July 16, 2020. The consensus earnings estimate is $0.32 per share on revenue of $21.26 billion and the Earnings Whisper ® number is $0.34 per share. Investor sentiment going into the company's earnings release has 34% expecting an earnings beat. Consensus estimates are for earnings to decline year-over-year by 56.76% with revenue decreasing by 26.99%. The stock has drifted higher by 8.4% from its open following the earnings release to be 15.2% below its 200 day moving average of $28.34. Overall earnings estimates have been revised lower since the company's last earnings release. On Tuesday, June 30, 2020 there was some notable buying of 24,305 contracts of the $28.00 call expiring on Friday, August 21, 2020. Option traders are pricing in a 7.8% move on earnings and the stock has averaged a 3.0% move in recent quarters.

(CLICK HERE FOR THE CHART!)


UnitedHealth Group, Inc. $291.23

UnitedHealth Group, Inc. (UNH) is confirmed to report earnings at approximately 5:55 AM ET on Wednesday, July 15, 2020. The consensus earnings estimate is $5.00 per share on revenue of $64.18 billion and the Earnings Whisper ® number is $5.11 per share. Investor sentiment going into the company's earnings release has 75% expecting an earnings beat. Consensus estimates are for year-over-year earnings growth of 38.89% with revenue increasing by 5.92%. Short interest has decreased by 12.8% since the company's last earnings release while the stock has drifted higher by 5.7% from its open following the earnings release to be 6.8% above its 200 day moving average of $272.66. Overall earnings estimates have been revised lower since the company's last earnings release. On Monday, June 29, 2020 there was some notable buying of 1,744 contracts of the $320.00 call and 1,730 contracts of the $240.00 put expiring on Friday, December 18, 2020. Option traders are pricing in a 5.5% move on earnings and the stock has averaged a 4.2% move in recent quarters.

(CLICK HERE FOR THE CHART!)


Johnson & Johnson $142.37

Johnson & Johnson (JNJ) is confirmed to report earnings at approximately 6:30 AM ET on Thursday, July 16, 2020. The consensus earnings estimate is $1.46 per share on revenue of $17.33 billion and the Earnings Whisper ® number is $1.53 per share. Investor sentiment going into the company's earnings release has 61% expecting an earnings beat. Consensus estimates are for earnings to decline year-over-year by 43.41% with revenue decreasing by 15.72%. Short interest has decreased by 18.0% since the company's last earnings release while the stock has drifted lower by 2.1% from its open following the earnings release to be 1.6% above its 200 day moving average of $140.18. Overall earnings estimates have been revised lower since the company's last earnings release. On Friday, July 10, 2020 there was some notable buying of 2,044 contracts of the $145.00 put expiring on Friday, August 21, 2020. Option traders are pricing in a 3.5% move on earnings and the stock has averaged a 1.8% move in recent quarters.

(CLICK HERE FOR THE CHART!)


DISCUSS!

What are you all watching for in this upcoming trading week?


I hope you all have a wonderful weekend and a great trading week ahead r/StockMarket.

submitted by /u/bigbear0083
[comments]



Source link

قالب وردپرس

Continue Reading

Trending